|
|
 Previous Article | Table of Contents | Next Article 
Genetic Polymorphisms in the Tumor Necrosis Factor Locus Influence
Non-Hodgkin's Lymphoma Outcome
Krzysztof Warzocha,
Patricia Ribeiro,
Jacques Bienvenu,
Pascal Roy,
Carole Charlot,
Dominique Rigal,
Bertrand Coiffier, and
Gilles Salles
From the Department of Hématologie, Laboratoire d'Immunologie
and Unité de Méthodologie en Cancérologie,
Université Claude Bernard (UPRES-JE 1879), and the Centre
Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite,
France; and the Etablissement de Transfusion Sanguine, Lyon, France.
Systemic release of tumor necrosis factor (TNF) and lymphotoxin-
(LT) has been found to contribute to the severity of non-Hodgkin's lymphoma (NHL). We investigated whether genetic polymorphisms in the
TNF locus, previously shown to influence TNF and LT genes expression, might contribute to these cytokines production and to the
clinical course of NHL. Genomic DNA from 273 lymphoma patients was
typed for TNF ( 308) polymorphism using an allele-specific polymerase
chain reaction (PCR) and for LT (+252) polymorphism with a
PCR-based restriction fragment length polymorphism. The presence of the
TNF allele involved in increased TNF gene transcription was associated
with higher plasma levels of this cytokine at the time of lymphoma
diagnosis ( 2 test, P = .013). An extended
haplotype analysis showed that the presence of at least two TNF or
LT high-producer alleles constituted a risk factor for first-line
treatment failure (2 test, P = .021), shorter
progression-free survival (log-rank test, P = .0007), and
overall survival (log-rank test, P = .012). In the subgroup
of 126 patients with diffuse large-cell lymphoma, the presence of two
or more TNF/LT high producing alleles contributed significantly to a
higher rate of relapse and progression (log-rank test, P = .045 and P = .027). In multivariate Cox regression models including the variables of the International Prognostic Index, the
TNF/LT haplotype status was found to be an independent risk factor
for progression-free survival (relative risk 2.33, 95% confidence
interval [1.17 to 4.64], P = .0053) and overall survival (relative risk 1.92, 95% confidence interval [0.63 to 5.80],
P = .081) of large-cell lymphoma patients. These results
indicate that genetic polymorphism leading to increased TNF production influences the outcome of NHL and suggest a pathophysiological role for
the genetic control of the immune response in lymphoid malignancies.
Blood, Vol. 91 No. 10 (May 15), 1998:
pp. 3574-3581
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. J. Novak, S. L. Slager, Z. S. Fredericksen, A. H. Wang, M. M. Manske, S. Ziesmer, M. Liebow, W. R. Macon, S. R. Dillon, T. E. Witzig, et al.
Genetic Variation in B-Cell-Activating Factor Is Associated with an Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma
Cancer Res.,
May 15, 2009;
69(10):
4217 - 4224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Tronchon, F. Vialard, M. El Sirkasi, H. Dechaud, J. Rollet, M. Albert, M. Bailly, P. Roy, C. Mauduit, P. Fenichel, et al.
Tumor necrosis factor-alpha -308 polymorphism in infertile men with altered sperm production or motility
Hum. Reprod.,
December 1, 2008;
23(12):
2858 - 2866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Anderson, R. M. Pfeiffer, J. S. Rapkin, G. Gridley, L. Mellemkjaer, K. Hemminki, M. Bjorkholm, N. E. Caporaso, and O. Landgren
Survival Patterns Among Lymphoma Patients With a Family History of Lymphoma
J. Clin. Oncol.,
October 20, 2008;
26(30):
4958 - 4965.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Habermann, S. S. Wang, M. J. Maurer, L. M. Morton, C. F. Lynch, S. M. Ansell, P. Hartge, R. K. Severson, N. Rothman, S. Davis, et al.
Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era
Blood,
October 1, 2008;
112(7):
2694 - 2702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-f. Cheung, G.-y. Huang, S.-b. Chen, X.-q. Liu, L. Xi, X.-c. Liang, M.-r. Huang, S. Chen, L.-s. Huang, X.-q. Liu, et al.
Inflammatory Gene Polymorphisms and Susceptibility to Kawasaki Disease and Its Arterial Sequelae
Pediatrics,
September 1, 2008;
122(3):
e608 - e614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Cerhan, S. M. Ansell, Z. S. Fredericksen, N. E. Kay, M. Liebow, T. G. Call, A. Dogan, J. M. Cunningham, A. H. Wang, W. Liu-Mares, et al.
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma
Blood,
December 15, 2007;
110(13):
4455 - 4463.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Cerhan, S. Wang, M. J. Maurer, S. M. Ansell, S. M. Geyer, W. Cozen, L. M. Morton, S. Davis, R. K. Severson, N. Rothman, et al.
Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival
Blood,
June 15, 2007;
109(12):
5439 - 5446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. C. Gray-Schopfer, M. Karasarides, R. Hayward, and R. Marais
Tumor Necrosis Factor-{alpha} Blocks Apoptosis in Melanoma Cells when BRAF Signaling Is Inhibited
Cancer Res.,
January 1, 2007;
67(1):
122 - 129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. M. Howell and M. J. Rose-Zerilli
Cytokine Gene Polymorphisms, Cancer Susceptibility, and Prognosis
J. Nutr.,
January 1, 2007;
137(1):
194S - 199S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Liu, Y. Berthier-Schaad, L. Plantinga, N. E. Fink, R. P. Tracy, W. H. Kao, M. J. Klag, M. W. Smith, and J. Coresh
Functional Variants in the Lymphotoxin-{alpha} Gene Predict Cardiovascular Disease in Dialysis Patients
J. Am. Soc. Nephrol.,
November 1, 2006;
17(11):
3158 - 3166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Wang, J. R. Cerhan, P. Hartge, S. Davis, W. Cozen, R. K. Severson, N. Chatterjee, M. Yeager, S. J. Chanock, and N. Rothman
Common Genetic Variants in Proinflammatory and Other Immunoregulatory Genes and Risk for Non-Hodgkin Lymphoma
Cancer Res.,
October 1, 2006;
66(19):
9771 - 9780.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Seidemann, M. Zimmermann, M. Book, U. Meyer, B. Burkhardt, K. Welte, A. Reiter, and M. Stanulla
Tumor Necrosis Factor and Lymphotoxin Alfa Genetic Polymorphisms and Outcome in Pediatric Patients With Non-Hodgkin's Lymphoma: Results From Berlin-Frankfurt-Munster Trial NHL-BFM 95
J. Clin. Oncol.,
November 20, 2005;
23(33):
8414 - 8421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Bilolikar, A. R. Nam, M. Rosenthal, J. C. Davies, D. C. Henderson, and I. M. Balfour-Lynn
Tumour necrosis factor gene polymorphisms and childhood wheezing
Eur. Respir. J.,
October 1, 2005;
26(4):
637 - 646.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.J. BISSELL, P.A. KENNY, and D.C. RADISKY
Microenvironmental Regulators of Tissue Structure and Function Also Regulate Tumor Induction and Progression: The Role of Extracellular Matrix and Its Degrading Enzymes
Cold Spring Harb Symp Quant Biol,
January 1, 2005;
70(0):
343 - 356.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Rollinson, J. M. Allan, G. R. Law, P. L. Roddam, M. T. Smith, C. Skibola, A. G. Smith, M. S. Forrest, K. Sibley, R. Higuchi, et al.
High-Throughput Association Testing on DNA Pools to Identify Genetic Variants that Confer Susceptibility to Acute Myeloid Leukemia
Cancer Epidemiol. Biomarkers Prev.,
May 1, 2004;
13(5):
795 - 800.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Lech-Maranda, L. Baseggio, J. Bienvenu, C. Charlot, F. Berger, D. Rigal, K. Warzocha, B. Coiffier, and G. Salles
Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma
Blood,
May 1, 2004;
103(9):
3529 - 3534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Majetschak, U. Obertacke, F. U. Schade, M. Bardenheuer, G. Voggenreiter, B. Bloemeke, and M. Heesen
Tumor Necrosis Factor Gene Polymorphisms, Leukocyte Function, and Sepsis Susceptibility in Blunt Trauma Patients
Clin. Vaccine Immunol.,
November 1, 2002;
9(6):
1205 - 1211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Juszczynski, E. Kalinka, J. Bienvenu, G. Woszczek, M. Borowiec, T. Robak, M. Kowalski, E. Lech-Maranda, L. Baseggio, B. Coiffier, et al.
Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome
Blood,
September 26, 2002;
100(8):
3037 - 3040.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Tsukasaki, C. W. Miller, T. Kubota, S. Takeuchi, T. Fujimoto, S. Ikeda, M. Tomonaga, and H. P. Koeffler
Tumor Necrosis Factor {{alpha}} Polymorphism Associated with Increased Susceptibility to Development of Adult T-Cell Leukemia/Lymphoma in Human T-lymphotropic Virus Type 1 Carriers
Cancer Res.,
May 1, 2001;
61(9):
3770 - 3774.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. Colombat, G. Salles, N. Brousse, P. Eftekhari, P. Soubeyran, V. Delwail, E. Deconinck, C. Haioun, C. Foussard, C. Sebban, et al.
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation
Blood,
January 1, 2001;
97(1):
101 - 106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Mira, A. Cariou, F. Grall, C. Delclaux, M.-R. Losser, F. Heshmati, C. Cheval, M. Monchi, J.-L. Teboul, F. Riche, et al.
Association of TNF2, a TNF-{alpha} Promoter Polymorphism, With Septic Shock Susceptibility and Mortality: A Multicenter Study
JAMA,
August 11, 1999;
282(6):
561 - 568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kumar, J. Short, and J. E. Parrillo
Genetic Factors in Septic Shock
JAMA,
August 11, 1999;
282(6):
579 - 581.
[Full Text]
[PDF]
|
|
|
|
|
